Japanese and Taiwanese shares recovered on Monday after last week’s AI-driven sell-off, but South Korea’s reversal highlighted fragile investor confidence.
CARSON CITY, Nev., Nov. 04, 2026 (GLOBE NEWSWIRE) — BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company“), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that
ZUSDURI® generated $68.0 million in revenue in the third quarter of 2026, representing 35% quarter-over-quarter growth The FDA accepted UroGen’s NDA for UGN-103 (next-generation novel mitomycin-based formulation) for review; PDUFA goal date
DALLAS and MANITOWOC, Wis., Nov. 04, 2026 (GLOBE NEWSWIRE) — Orion Energy Systems, Inc. (NASDAQ: OESX), today announced Sally Washlow and Per Brodin, CEO and CFO, will present at the Southwest IDEAS Investor
Recognition underscores global expert strength in damages, valuation and economic analysis for complex, high-stakes commercial disputes WASHINGTON, Nov. 04, 2026 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced that the
BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) — Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded an
FORT MYERS, Fla., Nov. 04, 2026 (GLOBE NEWSWIRE) — Alico, Inc. (“Alico” or the “Company”) (Nasdaq: ALCO) today announced that John Kiernan, the Company’s President and Chief Executive Officer, will present and
Lamb also stars in the brand’s NFL campaign A&F and Dallas Cowboys Wide Receiver CeeDee Lamb Launch Co-Designed Collection Lamb also stars in the brand’s NFL campaign A&F and Dallas Cowboys Wide
Submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in October 2026 seeking accelerated approval for CNM-Au8® in amyotrophic lateral sclerosis (ALS) Completed a $4.0 million registered
Irvine, Nov. 04, 2026 (GLOBE NEWSWIRE) — Pacific Health Care Organization, Inc., (the “Company”) (OTCQB: PFHO) filed yesterday with the Securities and Exchange Commission (the “SEC”) its quarterly report on Form 10-Q
NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that management
Follow